Skip to main content
Figure 2 | Critical Care

Figure 2

From: Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?

Figure 2

Cost-effectiveness acceptability curves for DrotAA within 24 hours of critical care admission. The curves show the probability that the intervention is cost-effective at different levels of willingness to pay for a quality-adjusted life year gain for the subsample who received Drotrecogin alfa (activated) (DrotAA) within 24 hours of admission to the critical care unit.

Back to article page

Critical Care

ISSN: 1364-8535